65 related articles for article (PubMed ID: 33785876)
1. Downregulation of ITGA6 confers to the invasion of multiple myeloma and promotes progression to plasma cell leukaemia.
Song S; Zhang J; Su Q; Zhang W; Jiang Y; Fan G; Qian C; Li B; Zhuang W
Br J Cancer; 2021 May; 124(11):1843-1853. PubMed ID: 33785876
[TBL] [Abstract][Full Text] [Related]
2. Secondary plasma cell leukaemia (PCL) with plasmablastic morphology.
Xu K; Nacheva E
J Hematop; 2024 Jun; 17(2):117-119. PubMed ID: 38580782
[TBL] [Abstract][Full Text] [Related]
3. Prognostic model for multiple myeloma progression integrating gene expression and clinical features.
Sun C; Li H; Mills RE; Guan Y
Gigascience; 2019 Dec; 8(12):. PubMed ID: 31886876
[TBL] [Abstract][Full Text] [Related]
4. Enhancing multiple myeloma staging: a novel cell death risk model approach.
Deng Z; Zhu H; Yuan Z; Zhang R; Wang Z; Li H; Yin L; Ruan X; Cheng Z; Li R; Peng H
Clin Exp Med; 2024 May; 24(1):95. PubMed ID: 38717497
[TBL] [Abstract][Full Text] [Related]
5. Microenvironment immune reconstitution patterns correlate with outcomes after autologous transplant in multiple myeloma.
Parmar H; Gertz M; Anderson EI; Kumar S; Kourelis TV
Blood Adv; 2021 Apr; 5(7):1797-1804. PubMed ID: 33787859
[TBL] [Abstract][Full Text] [Related]
6. Mortality from Multiple Myeloma Within One Year Following Autologous Stem Cell Transplantation: Defining an Ultra-high Risk Population.
Cherniawsky HM; AlAhwal H; Mourad YA; Forrest D; Gerrie A; Kuchenbauer F; Nantel SH; Narayanan S; Nevill T; Power M; Sanford D; Toze C; White J; Escano L; Sutherland H; Song K
Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):476-482. PubMed ID: 33814336
[TBL] [Abstract][Full Text] [Related]
7. Minocycline for symptom reduction in patients with multiple myeloma during maintenance therapy: a phase II placebo-controlled randomized trial.
Wang XS; Shi Q; Mendoza TR; Garcia-Gonzalez A; Chen TY; Kamal M; Chen TH; Heijnen C; Orlowski RZ; Cleeland CS
Support Care Cancer; 2021 Oct; 29(10):6099-6107. PubMed ID: 33792800
[TBL] [Abstract][Full Text] [Related]
8. Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma.
Ma MCJ; Tadros S; Bouska A; Heavican T; Yang H; Deng Q; Moore D; Akhter A; Hartert K; Jain N; Showell J; Ghosh S; Street L; Davidson M; Carey C; Tobin J; Perumal D; Vose JM; Lunning MA; Sohani AR; Chen BJ; Buckley S; Nastoupil LJ; Davis RE; Westin JR; Fowler NH; Parekh S; Gandhi M; Neelapu S; Stewart D; Bhalla K; Iqbal J; Greiner T; Rodig SJ; Mansoor A; Green MR
Haematologica; 2022 Mar; 107(3):690-701. PubMed ID: 33792219
[TBL] [Abstract][Full Text] [Related]
9. Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial.
Plesner T; Dimopoulos MA; Oriol A; San-Miguel J; Bahlis NJ; Rabin N; Suzuki K; Yoon SS; Ben-Yehuda D; Cook G; Goldschmidt H; Grosicki S; Qin X; Fastenau J; Garvin W; Carson R; Renaud T; Gries KS
Br J Haematol; 2021 Jul; 194(1):132-139. PubMed ID: 33822368
[TBL] [Abstract][Full Text] [Related]
10. A Review of Chimeric Antigen Receptor T-Cell Therapy for Myeloma and Lymphoma.
Atrash S; Moyo TK
Onco Targets Ther; 2021; 14():2185-2201. PubMed ID: 33814917
[TBL] [Abstract][Full Text] [Related]
11. Role of FDG PET in the staging of multiple myeloma.
Vicentini JRT; Bredella MA
Skeletal Radiol; 2022 Jan; 51(1):31-41. PubMed ID: 33813607
[No Abstract] [Full Text] [Related]
12. European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma.
Bruno B; Wäsch R; Engelhardt M; Gay F; Giaccone L; D'Agostino M; Rodríguez-Lobato LG; Danhof S; Gagelmann N; Kröger N; Popat R; Van de Donk NWCJ; Terpos E; Dimopoulos MA; Sonneveld P; Einsele H; Boccadoro M
Haematologica; 2021 Aug; 106(8):2054-2065. PubMed ID: 33792221
[TBL] [Abstract][Full Text] [Related]
13. Remote controlling of CAR-T cells and toxicity management: Molecular switches and next generation CARs.
Moghanloo E; Mollanoori H; Talebi M; Pashangzadeh S; Faraji F; Hadjilooei F; Mahmoodzadeh H
Transl Oncol; 2021 Jun; 14(6):101070. PubMed ID: 33789222
[TBL] [Abstract][Full Text] [Related]
14. Functional characterization of PD1+TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade.
Roussel M; Le KS; Granier C; Llamas Gutierrez F; Foucher E; Le Gallou S; Pangault C; Xerri L; Launay V; Lamy T; Tartour E; Olive D; Fest T
Blood Adv; 2021 Apr; 5(7):1816-1829. PubMed ID: 33787861
[TBL] [Abstract][Full Text] [Related]
15. Extramedullary Multiple Myeloma with Hepatic Involvement.
Singh M; Singh H; Pham P; Rizvi B; Rao R
Cureus; 2021 Feb; 13(2):e13515. PubMed ID: 33786223
[TBL] [Abstract][Full Text] [Related]
16. The fatty acid elongase ELOVL6 regulates bortezomib resistance in multiple myeloma.
Lipchick BC; Utley A; Han Z; Moparthy S; Yun DH; Bianchi-Smiraglia A; Wolff DW; Fink E; Liu L; Furdui CM; Lee J; Lee KP; Nikiforov MA
Blood Adv; 2021 Apr; 5(7):1933-1946. PubMed ID: 33821992
[TBL] [Abstract][Full Text] [Related]
17. Infections in hematopoietic stem cell transplant patients admitted to Hematology intensive care unit: a single-center study.
Barlas T; İnci K; Aygencel G; Türkoğlu M; Tunçcan ÖG; Can F; Aydın Kaynar L; Özkurt ZN; Yeğin ZA; Yağcı M
Hematology; 2021 Dec; 26(1):328-339. PubMed ID: 33818297
[TBL] [Abstract][Full Text] [Related]
18. Clinical Application of Liquid Biopsy in Non-Hodgkin Lymphoma.
Lv L; Liu Y
Front Oncol; 2021; 11():658234. PubMed ID: 33816315
[TBL] [Abstract][Full Text] [Related]
19. Pros and Cons for Fluorescent
Ikbal Atli E; Gurkan H; Onur Kirkizlar H; Atli E; Demir S; Yalcintepe S; Kalkan R; Demir AM
Balkan J Med Genet; 2020 Nov; 23(2):59-64. PubMed ID: 33816073
[TBL] [Abstract][Full Text] [Related]
20. Pulmonary infection with Penicillium citrinum in a patient with multiple myeloma.
Beena H; Gupta M; Kindo AJ
Indian J Med Microbiol; 2021 Apr; 39(2):259-261. PubMed ID: 33814124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
